Pilot Study of Velcade® in IgA Nephropathy

Exclusion Criteria

• •1. Low platelet count and neutrophil count within certain limits defined for enrollment.
• •2. Underlying peripheral neuropathy.
• •3. Having cardiac problems, such as myocardial infarction, heart failure, uncontrolled angina, severe uncontrolled ventricular arrhythmias, or electrocardiographic evidence of acute ischemia or active conduction system abnormalities.
• •4. Allergic to VELCADE®, boron or mannitol.
• •5. Female subjects who are pregnant or breast-feeding.
• •6. Recent use of investigational drug within 14 days before enrollment.
• •7. Having serious medical conditions and infections (including HIV,or hepatitis B or C) or psychiatric illness likely to interfere with participation in the study.
• •8. Diagnosed or treated for cancer within 3 years of participation in the study, with the exception of complete resection of basal cell carcinoma or squamous cell carcinoma of the skin, and in situ malignancy, or low-risk prostate cancer after curative therapy.